Voquezna denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for voquezna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Voquezna on Medical-Necessity Grounds

Voquezna (vonoprazan) is a PCAB-class acid blocker with FDA-approved indications in gastroenterology, including Helicobacter pylori eradication regimens and erosive esophagitis. UHC's medical-necessity denials for voquezna typically arise because the submitted record does not clearly document: (1) the specific diagnosis being treated, (2) the clinical severity or diagnostic workup that supports drug therapy, or (3) why voquezna specifically — rather than a more established, lower-cost alternative — is medically necessary for this patient.

These denials turn on documentation completeness. The clinical case is usually solid; the record just needs to show it.

## Your Appeal Rights

• Internal appeal (ERISA §503 / ACA): File within the deadline stated on the denial notice, typically 180 days. Request that the appeal be reviewed by a physician with gastroenterology expertise.
• External review (ACA §2719): After exhausting internal appeal, request binding independent external review within approximately four months of the final internal denial.
• Expedited review: Request expedited process if delay would significantly harm the patient (e.g., active H. pylori infection with complications, severe erosive disease).

## Documentation to Gather

1. Diagnostic workup — endoscopy report, H. pylori test results (breath test, stool antigen, or biopsy), or other objective diagnostic studies confirming the condition being treated. 2. Clinical severity documentation — endoscopic grading of esophagitis (if applicable), symptom severity documentation, or laboratory/pathology findings supporting the need for treatment. 3. Prior acid-suppressive therapy history — dates and durations of PPI use, with outcomes (inadequate response, recurrence, tolerability issues) documented in the chart. 4. Prescriber medical-necessity letter — a letter from the treating gastroenterologist or primary care provider explaining: - The specific diagnosis and objective findings - Why vonoprazan is the appropriate agent for this patient - How prior treatments have or have not addressed the clinical problem - Reference to the applicable guideline organization (e.g., ACG) without asserting specific statistics 5. Current medication list — showing active and recent acid-suppressive agents.

## Criteria-Mapping Structure

Obtain UHC's medical policy for vonoprazan and the FDA-approved prescribing label. Create a mapping table:

| UHC / Label Criterion | Chart Evidence Provided | |---|---| | Diagnosis confirmation | Endoscopy / H. pylori test result; ICD-10 code | | Clinical severity documented | Endoscopic grade or symptom severity note | | Prior therapy considered | PPI history with outcomes | | Prescriber specialty (if required) | Gastroenterologist or treating physician credentials |

A well-organized appeal letter that walks the reviewer through each criterion — with chart references — is your strongest tool. Attach the actual records, not just summaries.